Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

CAUSES OF UNSUCCESSFUL RANIBIZUMAB TREATMENT IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION IN CLINICAL SETTINGS

Cohen, Salomon Y., Oubraham, Hassiba, Uzzan, Joel, Dubois, Lise, Tadayoni, Ramin · 2012 · Retina

Abstract

In Brief Purpose: To identify the causes of loss of vision after ranibizumab therapy in patients with exudative age-related macular degeneration treated in three clinical settings. Methods: A retrospective multicentric analysis of 290 consecutive eyes comprising cohorts from 3 clinical settings showed that 21 eyes lost ≥15 letters on the Early Treatment Diabetic Retinopathy Study chart 1 year after the start of ranibizumab treatment. Fundus images of these eyes were analyzed by two independent readers to investigate the causes of visual loss. The three cohorts were compared. A search was made for factors predisposing to visual loss. A second analysis was performed to compare the baseline characteristics of patients who gained (visual acuity gainers) or lost (visual acuity losers) ≥15 letters. Results: Among the 290 eyes included, the proportions from each center experiencing visual loss were not significantly different (mean, 7.24%, P = 0.2631). Mean visual loss of affected eyes was 27 letters. There was no significant difference between these eyes and others as regards age and gender of patients, laterality, type of choroidal neovascularization, number of visits, or initial visual acuity. Visual loss was secondary to the progression of atrophy in eight eyes, fibrosis in five eyes, a combination of fibrosis and atrophy in three eyes, severe subretinal hemorrhage in three eyes, and retinal pigment epithelial tear in two eyes. A significant difference between visual acuity gainers and losers was observed for 2 parameters: age of patients, 80.9 ± 5.3 years in visual acuity losers versus 77.5 ± 7.3 years in visual acuity gainers (P = 0.0473) and visual acuity at diagnosis, respectively, 56.2 ± 11.2 versus 49.0 ± 12.0 (P = 0.0288). Conclusion: Although uncommon, visual loss may occur during ranibizumab treatment and is because of the natural course of age-related macular degeneration in most cases. A multicentric, retrospective study of 290 consecutive eyes treated by ranibizumab showed that at 1 year, 21 eyes (7.2%) lost ≥15 on the Early Treatment Diabetic Retinopathy Study chart. Visual loss was secondary to trophy (eight eyes), fibrosis (five eyes), fibrosis and atrophy (three eyes), subretinal hemorrhage (three eyes), and retinal pigment epithelial tear (two eyes).

Overview

Integrity signals

Registry

Crossref · 10.1097/iae.0b013e318240a516

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 35 references

Cited by

See all 61

Metadata

Authors
Cohen, S. Y., Oubraham, H., Uzzan, J., Dubois, L., & Tadayoni, R.
Affiliations
Hôpital Lariboisière (FR)
Corresponding author
  • Cohen, Salomon Y.
  • Dubois, Lise
Venue
Retina
Published
2012-09
Volume
32
Issue
8
Pages
1480-1485
ISSN
0275-004X (ISSN-L)
OpenAlex
W2086688665
Cited by
61
References
35
Citations by year
2025: 10 · 2024: 8 · 2023: 6 · 2022: 3 · 2021: 4 · 2020: 6 · 2019: 3 · 2018: 3 · 2017: 4 · 2015: 4 · 2014: 5 · 2013: 4 · 2012: 1
FWCI
4.19
Type
journal article
Language
en
Open access
closed
Locations
  • Retina (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
Keywords
ranibizumab, neovascular age-related macular degeneration, choroidal neovascularization, visual acuity loss, macular atrophy, subretinal fibrosis, subretinal hemorrhage, retinal pigment epithelial tear, patient age, natural disease course, retinal imaging
MeSH terms
Ranibizumab, Aged, Aged, 80 and over, Atrophy, Exudates and Transudates, Female, Fibrosis, Humans, Male, Middle Aged, Retina, Retrospective Studies, Risk Factors, Vision Disorders, Visual Acuity, Treatment Failure, Angiogenesis Inhibitors, Tomography, Optical Coherence, Wet Macular Degeneration, Intravitreal Injections, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CAUSES OF UNSUCCESSFUL RANIBIZUMAB TREATMENT IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION IN CLINICAL SETTINGS. https://app.cochat.ai/papers/10.1097/iae.0b013e318240a516
The paper
Cohen, S. Y., Oubraham, H., Uzzan, J., Dubois, L., & Tadayoni, R. (2012). CAUSES OF UNSUCCESSFUL RANIBIZUMAB TREATMENT IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION IN CLINICAL SETTINGS. Retina. https://doi.org/10.1097/iae.0b013e318240a516

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.